Feedback / Questions
mirikizumab (LY3074828) - Eli Lilly
Mirikizumab: Top-line data from P3 trials LUCENT 1 (NCT03518086), LUCENT 2 (NCT03524092) and LUCENT 3 (NCT03519945) for ulcerative colitis in 2020
(Eli Lilly)
-
Dec 18, 2019 -
2020 Financial Guidance Call
P3 data: top line
https://investor.lilly.com/static-files/2ebfafdb-ce4a-4fc9-9c40-5e0178db8527
Dec 18, 2019
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious